Related Experiment Video
Updated: Jan 28, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Cancer Vaccines
Peter J DeMaria1, Marijo Bilusic2
1Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, Room B2L312, Bethesda, MD 20892, USA.
Abstract:
Cancer vaccines are a promising strategic approach within the rapidly growing field of immuno-oncology. Therapeutic cancer vaccines are distinct from prophylactic vaccines and vary by both target antigen and vaccine platform. There are currently 3 FDA-approved therapeutic cancer vaccines: intravesical BCG live, sipuleucel-T, and T-VEC. Prior clinical trials have shown that vaccines are generally well tolerated, exhibit unique kinetics, can target tumor neoantigens, and induce antigen cascade. Ongoing clinical trials seek to improve vaccine efficacy either by targeting novel antigens or by combining vaccines with standard-of-care therapies or other immune therapies.
Insights
Therapeutic cancer vaccines, a key part of immuno-oncology, are well-tolerated and can target tumors. Ongoing research aims to enhance their effectiveness through new targets and combination therapies.
Area of Science:
- Immuno-oncology
- Cancer vaccine development
Background:
- Therapeutic cancer vaccines represent a significant advancement in oncology.
- They differ from prophylactic vaccines, utilizing diverse target antigens and platforms.
- Three FDA-approved therapeutic cancer vaccines include intravesical BCG live, sipuleucel-T, and T-VEC.
Purpose of the Study:
- To summarize the current landscape of therapeutic cancer vaccines.
- To highlight their distinct characteristics and clinical trial findings.
- To outline future directions in cancer vaccine research.
Main Methods:
- Review of existing literature and FDA-approved therapeutic cancer vaccines.
- Analysis of clinical trial data regarding vaccine tolerability and kinetics.
- Identification of ongoing research strategies for improved efficacy.
Main Results:
- Therapeutic cancer vaccines are generally well-tolerated in clinical trials.
- Vaccines demonstrate unique kinetic profiles and the ability to induce antigen cascade.
- Existing vaccines target specific antigens, with potential for neoantigen targeting.
Conclusions:
- Therapeutic cancer vaccines are a promising strategy in immuno-oncology.
- Further research focuses on novel antigen targets and combination therapies to boost efficacy.
- Ongoing trials are crucial for advancing cancer treatment through vaccination.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

